Aegea Biotechnologies, Inc. ( “Aegea”) ( www.aegeabiotech.com), a biotechnology company focusing on the development and commercialization of next generation nucleic acid clinical diagnostic technologies, announces the issuance of 7 additional key US patents related to its core next generation nucleic acid clinical diagnostic technologies, including applications related to COVID-19 diagnostic testing under the c
NEW YORK, NY and SAN DIEGO, CA, May 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Aegea Biotechnologies, Inc. ( “Aegea”) ( www.aegeabiotech.com), a biotechnology company focusing on the development and commercialization of next generation nucleic acid clinical diagnostic technologies, announces the issuance of 7 additional key US patents related to its core next generation nucleic acid clinical diagnostic technologies, including applications related to COVID-19 diagnostic testing under the collaboration agreement with Tauriga Sciences Inc.. (OTCQB: TAUG) (“Tauriga”).
The collection of recently issued, key US patents include U.S. Patent 10,174,352 entitled METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS ON SOLID SUPPORT, U.S. Patents 10,081,825 and 10,590,453, entitled METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS UTILIZING A CIRCULARIZED TEMPLATE PREPARED FROM A TARGET NUCLEIC ACID, U.S. Patent 10,066,262, entitled METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS UTILIZING HARIPIN LOOP OR DUPLEX PRIMERS, U.S. Patent 10,202,629, entitled METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS UTILIZING CLAMP OLIGONUCLEOTIDES, U.S. Patent 10,072,290, entitled METHODS FOR AMPLIFYING FRAGMENTED TARGET NUCLEIC ACIDS UTILIZING AN ASSEMBLER SEQUENCE, U.S. Patent 10,179,931, entitled METHODS FOR IMMOBILIZING TARGET NUCLEIC ACIDS UTILIZING COMBINATORIAL CAPTURE PROBES. These patents add to an already existing patent estate that includes US Patent 9,834,817, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS, as well as others.
In total, Aegea Biotechnologies, Inc. has obtained 10 issued U.S. patents and 33 foreign equivalents. The foreign jurisdictions include Europe, China, Japan, South Korea, and Canada. Collectively, these patents are directed to a broad array of enabling next generation nucleic acid technology as well as molecular diagnostic testing technologies that include nucleic acid PCR and isothermal amplification, the specific capture of nucleic acid fragments of interest, the use of fragmented targets, and methods for ultra-high sensitive detection of genetic alterations of interest.
“We are very pleased by the issuance of these additional Aegea patents and expect many more patent allowances both in the U.S. and worldwide,” said Lyle Arnold, Ph.D., Aegea’s President and CEO. “Our goal is to leverage Aegea’s patented technologies to advance biotechnology and to aid in improving human health, particularly in the area of clinical diagnostics. In today’s environment, we are focusing on bringing additional options for rapidly and precisely detecting COVID-19.”
Tauriga’s CEO, Mr. Seth Shaw, states, “Several of Aegea’s patented, cutting edge technologies are being applied to develop precise COVID-19 tests that are both affordable and accessible. Tauriga is enthusiastic about the progress being realized, with respect to its Collaboration Agreement with Aegea.”
ABOUT AEGEA BIOTECHNOLOGIES, INC.
Aegea Biotechnologies, Inc., located in San Diego, California, is a biotechnology company focusing on the development and commercialization of next generation nucleic acid technologies. A primary focus for the company is nucleic acid technology innovations that embrace molecular diagnostic assays, qPCR technologies, sequencing methods including both Sanger and NGS, and rapid point-of-care COVID-19 testing.
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.com
Complimentary to the Company’s retail business, are its two ongoing biotechnology initiatives. The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.
The Company is headquartered in New York City and operates a regional office in Barcelona, Spain. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
CONTACT INFORMATION:
TAURIGA SCIENCES, INC.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
AEGEA BIOTECHNOLOGIES, INC.
Stella M. Sung, Ph.D.
Chief Business Officer
Email: ssung@aegeabiotech.com
Corp. Website: www.aegeabiotech.com
